PubMed Health⌕ Search

Biomedical subjects

A Pfleiderer

Publications and source records attributed to A Pfleiderer.

At least 73 records · Page 4Linked to original sources
PubMed1980

Destruction of human solid tumors by alkyl lysophospholipids.

Alkyl lysophospholipids (ALP) are synthetic analogs of the naturally occurring 2-lysophosphatidylcholine. The effect of ALP on the proliferation of 22 different gynecologic malignant tumors in humans was studied in vitro. ALP caused progressive death of tumor cells over 24-96 hours. In addition, tumor specimens from the tested human tumors were xenotransplanted into NMRI nude mice. ALP induced a highly significant retardation of the in vivo growing human tumors. Neither oral nor iv administration of these compounds caused any recognizable side effects.

Adenocarcinoma↗
PubMed1979

[Pressing problems of after care of patients with cancers of the cervix and corpus uteri].

A modern and optimal follow-up treatment of patients with uterine cancer requires a detailed knowledge of this disease and its sequelae. Incidence and localisation of cervical and endometrial cancers as well as kind and incidence of therapeutical side effects are demonstrated in the cases of the Gynecological University Hospital of Freiburg, GFR. A study of the psychosexual situation 2--4 years after therapy of uterine cancer is reported. Actual state of social assurances for cancer patients in the German Federal Republic is pointed out. The dates allow to draw conclusions for the follow-up of individual cases.

Adult↗
PubMed1979

[Absorption and distribution of cytoplasmic organ lysates (conjunctisan A eye drops) following intraconjunctival application (author's transl)].

The absorption and transport pathways of Conjunctisan A were determined, and its mode of action clarified, by means of radioactive labeling. A dose of 0.5 ml of this drug, labeled with I131, was applied to the conjunctival sacs of rats and rabbits. After six hours there was highly significant enrichment in the ocular tissues. The highest degree of enrichment was found in the uvea, i.e., the ciliary body, choroid and retina. However, there was also moderate enrichment in the lens and the vitreous. It was proved immunologically that the radioactivity was identical with the original Conjunctisan A molecule. In particular, it as demonstrated that the enriched Conjunctisan A in the aqueous humor precipitates with the specific antibody.

Absorption↗
PubMed1977

[Investigations about the incorporation of nucleotide precursors in single cell suspensions of ovarian- and cervix-carcinomas under the influence of cytostatic therapy (author's transl)].

The behaviour of 34 carcinomas of the cervix and 30 ovarian carcinomas under the influence of cytostatic agents was investigated in vitro by the method of Volm et al. The ovarian carcinomas showed a significantly higher incorporation rate of nucleotide precursors in the single cell suspensions. The incorporation rate in "chemosensitive" carcinomas was higher than in "chemoresistent" carcinomas independent of the type of the carcinomas. Carcinomas with a high decrease in incorporation rates of nucleotide precursors under the influence of cytostatic drugs were called chemosensitive. A cyclophosphamide-sensitivity in vitro was found in 9% of the carcinomas of the cervix and in 34% of the ovarian carcinomas. An adriamycin-sensitivity in vitro could be shown in 17% of the carcinomas of the cervix and in 46% of the ovarian carcinomas. These findings agree well with the experiences of cytostatic therapy of these carcinomas.

Bleomycin↗
PubMed1976

[The problems of prophylactic chemotherapy, the second-look operation and the maintenance of the remission in the treatment of ovarian cancer (author's transl)].

The results of the treatment of 1022 ovarian cancers were reviewed and the problems of prophylactic chemotherapy, a second look operation and the maintenance of the remission were studied. In ovarian cancers of stage 1 and stage 2, a post-operative prophylactic chemotherapy is useful only in cases with tumor cells in the secretions of the pouch of Douglas or in the ascites and in cases where a sensitivity to the chemotherapy can be assumed. In about 50% of primarily inoperable stage 3 ovarian cancers, the random treatment with cyclophosphamide (Endoxan) results in a clinical remission. A significant five year cure rate can only be obtained if the uterus and the adnexa are removed. Radical operation during the remission appears to be very important for survival of the patient. For the maintenance of the remission continuous chemotherapy for at least 2 years following treatment by operation and radiotherapy is necessary.

Castration↗
PubMed1976

[Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas (author's transl)].

Ifosfamide or cyclophosphamide was employed in an alternating series in 49 advanced ovarian carcinomas. The two cytostatic drugs were given in single massive doses. In primary inoperable ovarian carcinomas at stage III and IV a partial remission occurred in 8 of 19 cases (42%) after treatment with cyclophosphamide. Ifosfamide produced a partial or complete remission in 9 of 11 cases (82%). However, 3 patients treated by ifosfamide died within 3 weeks after the administration of the first massive dose. Regarding these cases as failures there was a remission in 9 of 14 cases (64%). Cyclophosphamide enabled a secondary radical operation in 7 of 19 (37%), ifosfamide in 6 of 14 cases (43%). The intervals between an exploratory laparotomy and the secondary radical operation were 5 months on the average for the two cytostatic drugs.

Cyclophosphamide↗